Management of Hypercalcemia of Malignancy

Initial Assessment and Severity Classification

The American College of Physicians recommends measuring corrected serum calcium using the formula: Corrected calcium (mg/dL) = Total calcium (mg/dL) - 0.8 × [Albumin (g/dL) - 4], or preferably measure ionized calcium directly 2, 3
Classify severity to guide urgency: mild (10-11 mg/dL), moderate (11-12 mg/dL or 12-13.5 mg/dL), or severe (>14 mg/dL) 1, 2
Obtain serum intact PTH, PTHrP, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, phosphorus, magnesium, creatinine, and albumin to determine the underlying mechanism 1, 2
Malignancy-associated hypercalcemia is characterized by suppressed iPTH levels, elevated PTHrP, and low or normal calcitriol levels 1, 2

Administer IV normal saline immediately to correct hypovolemia and promote calciuresis, targeting urine output ≥100 mL/hour 1, 2, 3
Hydration should ideally start at least 48 hours before tumor-specific therapy when possible 4
Zoledronic acid is superior to pamidronate and should be the first-choice bisphosphonate 5, 1
Administer zoledronic acid 4 mg as a single IV infusion over 15 minutes in 100 mL volume 5, 1
Zoledronic acid normalizes calcium in approximately 50% of patients by day 4 and provides longer response duration than pamidronate 5, 1

Denosumab 120 mg subcutaneously is indicated for bisphosphonate-refractory hypercalcemia or patients with renal insufficiency 1, 2, 3
Denosumab reduces serum calcium in 64% of patients with bisphosphonate-refractory hypercalcemia 1
Monitor calcium levels closely post-denosumab treatment due to significant risk of hypocalcemia 1, 3

Monitor serum creatinine, calcium, and urinary albumin before and during bisphosphonate therapy 5, 2
Discontinue bisphosphonates if unexplained albuminuria >500 mg/24 hours OR serum creatinine increases >0.5 mg/dL OR absolute creatinine >1.4 mg/dL in patients with normal baseline 5
Perform baseline dental examination and monitor for osteonecrosis of the jaw with chronic bisphosphonate use 1, 3

Median survival after discovery of malignant hypercalcemia in lung cancer patients is approximately 1 month 1
Treatment of the underlying malignancy is essential for long-term control of hypercalcemia 2